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development of extensive c GVHD coincided with rapid
reversion of declining PB CD34+ DC. Restoration of PB CD34+
DC after cGVHD was associated with development of potent
GVL effect because both patients have remained disease free
for 12 and 15 months, respectively (Fig2).
Conclusions: Declining PB CD34+ DC associates with higher
risk for relapsed disease after allo-HCT. MRD and GVL can be
monitored serially by a non-invasive PB CD34+ DC assay. GVL
associates with cGVHD in patients with MDS and AML.
Monitoring of PB CD34+ DC may identify at-risk patients
eligible for early withdrawal of immunosuppression or post-
transplant allograft modulation.Figure 2.430
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Introduction: The concentration of cyclosporine A (CsA)
after allogeneic stem cell transplantation has been reported
to be important in prevention of acute graft versus host
disease (aGVHD). The target concentration and method of
monitoring CsA concentration varies between transplant
centers. More knowledge is needed to tailor the intensity of
post transplant immunosuppression in relation to the risk of
aGVHD, disease relapse and nephrotoxicity.
Methods: We retrospectively analyzed data from 48 adult
patients, who consecutively underwent myeloablative allo-
geneic stem cell transplantation in the years 2010 and 2011
at Rigshospitalet, Copenhagen. Transplant indications were
AML (n¼18), ALL (n¼14), MDS (n¼3), SAA (n¼6), MM (n¼2)
and other (n¼5). Whole blood concentration of CsA was
measured once daily 8 hours after the administration of CsA.
The median CsA concentration in weeks 1 to 4 was calcu-
lated, and patients were divided into two equally sized
groups according to the median CsA concentration. Renal
impairment was deﬁned as doubling of serum creatinineFigure 1.during the ﬁrst 28 days after transplantation. Comparison of
groups with or without aGVHD grade II or more was done
using the chi square test for categorical variables. Variables
with a p<0.1 were further analyzed using multivariate lo-
gistic regression. Probability of developing aGVHD was
calculated using the cumulative incidence procedure with
death as competing event.
Results: Themedian concentrations of CsA in each of the ﬁrst
4 weeks after transplantation are shown in ﬁgure 1. The
proportion of patients with aGVHD grade II-IV was higher in
those with CsA levels below the median 2 weeks after
transplantation (p¼0.019). This association was also found
when assessing the cumulative incidence of aGVHD with
death as competing event (p¼0.012, ﬁgure 2), and further-
more remains signiﬁcant in multivariate analysis after
adjusting for donor relation, TBI and donor sex. All cases of
aGVHD (n¼20) occurred after 2 weeks from time of trans-
plantation. CsA levels at week 1, 3 and 4 did not affect the risk
of aGVHD. Importantly, CsA levels were not correlated with
excess risk of developing renal impairment. No relation was
found between CsA levels and death from relapse (P¼0.73).
Conclusion: This study indicates a close relationship be-
tween the concentration of CsA in the early post-transplant
period and development of aGVHD grade II or more. Neph-
rotoxicity was not an obstacle for achieving higher concen-
trations of CsA. Therefore, close monitoring of the CsA
concentration in the early transplant period is important in
maintaining CsA within target concentration and thus pre-
venting development of aGVHD. Target concentration of CsA
early in the post transplant course should possibly be
adjusted to higher levels than we observed in this series of
patients. Cumulative incidence of aGVHD (1) and death (2)
for groups with high and low CsA.431
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In an adult study, Nash et al. (Blood, 2000) recommended to
maintain tacrolimus levels between 10-20ng/ml for aGVHD
prophylaxis. The optimal range for tacrolimus levels in
